New cancer drug combo enters first human tests
NCT ID NCT03891953
Summary
This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researchers will also check how the drugs move through the body and look for any early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.